Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug trial aims to tame rare blood disorder flares

NCT ID NCT04191304

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a drug called benralizumab, given as an injection every 4 weeks, can help control Hypereosinophilic Syndrome (HES). HES is a rare disorder where high levels of white blood cells cause inflammation and damage to organs. The trial will see if the drug can prevent symptom flares and reduce the need for steroid medications in 134 patients aged 12 and older who are already on stable treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    La Jolla, California, 92037, United States

  • Research Site

    Atlanta, Georgia, 30324, United States

  • Research Site

    Bethesda, Maryland, 20892, United States

  • Research Site

    Ann Arbor, Michigan, 48105, United States

  • Research Site

    Durham, North Carolina, 27705, United States

  • Research Site

    Cleveland, Ohio, 44106, United States

  • Research Site

    Columbus, Ohio, 43212, United States

  • Research Site

    Salt Lake City, Utah, 84112, United States

  • Research Site

    Rosario, 2000, Argentina

  • Research Site

    Innsbruck, 6020, Austria

  • Research Site

    Brussels, 1070, Belgium

  • Research Site

    Edegem, 2650, Belgium

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Tianjin, 300020, China

  • Research Site

    Xiamen, 361015, China

  • Research Site

    Zhengzhou, 450008, China

  • Research Site

    København Ø, 2100, Denmark

  • Research Site

    Lille, 59037, France

  • Research Site

    Pessac, 33604, France

  • Research Site

    Strasbourg, 67091, France

  • Research Site

    Suresnes, 92151, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Hanover, 30625, Germany

  • Research Site

    Kirchheim, 73230, Germany

  • Research Site

    Mannheim, 68167, Germany

  • Research Site

    Ahmedabad, 380013, India

  • Research Site

    Ajmer, 305001, India

  • Research Site

    Delhi, 110029, India

  • Research Site

    Haifa, 34362, Israel

  • Research Site

    Holon, 58100, Israel

  • Research Site

    Jerusalem, 91120, Israel

  • Research Site

    Kfar Saba, 44218, Israel

  • Research Site

    Petah Tikva, 49100, Israel

  • Research Site

    Ramat Gan, 5265601, Israel

  • Research Site

    Rehovot, 76100, Israel

  • Research Site

    Tel Aviv, 64239, Israel

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Chiba, 260-0852, Japan

  • Research Site

    Hamamatsu, 431-3192, Japan

  • Research Site

    Ichikawa-shi, 272-8516, Japan

  • Research Site

    Kawasaki-shi, 211-8510, Japan

  • Research Site

    Nishinomiya-shi, 663-8501, Japan

  • Research Site

    Osaka, 530-8480, Japan

  • Research Site

    Sendai, 980-8574, Japan

  • Research Site

    Rotterdam, 3015 GD, Netherlands

  • Research Site

    Chęciny, 26-060, Poland

  • Research Site

    Gdansk, 80-214, Poland

  • Research Site

    Lodz, 90-153, Poland

  • Research Site

    Seoul, 5505, South Korea

  • Research Site

    Santander, 39010, Spain

  • Research Site

    London, W2 1NY, United Kingdom

Conditions

Explore the condition pages connected to this study.

HYPEREOSINOPHILIC SYNDROME